Zynex, Inc. (OTCBB: ZYXI),
a provider of pain management systems and electrotherapy products for
medical patients with functional disability, has introduced a Lumbar
Sacral Orthosis (LSO) Back Support to its sales force effective
immediately. The product is manufactured by a subsidiary of the British
company BSN Medical and already has established reimbursement coding and
pricing with insurance carriers as well as Medicare. The product is
available in 8 different sizes, provides support for the lumbar area and
is usually prescribed by physicians for Chronic Back Pain, Lumbar
Instability, Herniated Lumbar Discs, Degenerative Disc Disease,
Spondylosis, Stenosis and Post-Op Rehabilitation.
Zynex’s CEO, Thomas Sandgaard, commented: “We are excited to add this
product to our existing line of electrotherapy products. It lends itself
well to the market for pain management and our existing sales force will
have a more complete offering for doctors and patients.”
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells
its own design of electrotherapy medical devices in two distinct
markets: standard digital electrotherapy products for pain relief and
pain management; and the NeuroMove(TM) for stroke and spinal
cord injury (SCI) rehabilitation. Zynex's product lines are fully
developed, FDA-cleared, commercially sold, and have been developed to
uphold the Company's mission of improving the quality of life for
patients suffering from impaired mobility due to stroke, spinal cord
injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to
obtain additional capital in order to grow our business, larger
competitors with greater financial resources, the need to keep pace with
technological changes, our dependence on the reimbursement from
insurance companies for products sold or rented to our customers,
acceptance of our products by health insurance providers, acceptance of
our products by hospitals and clinicians, our dependence on third party
manufacturers to produce our goods on time and to our specifications,
implementation of our sales strategy including a strong direct sales
force, the uncertain outcome of pending material litigation and other
risks described in our 10-K Report for the year ended December 31, 2008.
Zynex, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com
